Ozempic Teeth, Muscle Loss: Some of the Buzziest GLP-1 Side Effects
Reported by MedPage Today. Read the original →
The headline reports on side effects associated with Semaglutide, specifically mentioning "Ozempic teeth" and muscle loss. It suggests that these effects are among the most discussed or notable side effects of GLP-1 medications.
Summarised by a model from MedPage Today's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.Human · RCT · 2026
- Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?Human · RCT · 2026
- Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?Human · Case report · 2026
14 compounds tracked · 344 studies on file · 150 in humans
What the headline doesn't tell you
- Semaglutide has 60 studies on file, 32 of them in humans, the newest published 2026.
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.